By comparing current perspectives with current evidence in literature, this study identified that a significant number of specialists were unsure of the role of several biomarkers such as CDX2, EGFR, KRAS and BRAF status on the prognostication of colorectal cancer and its influence on adjuvant therapy in stage II disease. This evidence concerns the gene KRAS and colorectal cancer.